TSX Biotech Company Develops Potential Treatment for Type 2 Diabetes 

(MENAFN Press) TSX Biotech Company Develops Promising Potential Treatment for Type 2 Diabetes and Obesity

Sirona Biochem (TSX-V: SBM, OTC: SRBCF) Uses Carbohydrate Molecules to Develop Sodium Glucose Transporter (SGLT) Inhibitors

New York, New York “ April 12, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a biotech company snapshot for Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), a company using
Carbohydrate-based molecules to develop Sodium Glucose Transporter (SGLT) inhibitors for Type 2 diabetes and obesity as one of its key products in its pipeline.

The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.

Sodium Glucose Transporter (SGLT) Inhibitors “ Diabetes & Obesity
Sirona Biochem is developing SGLT inhibitors for Type 2 diabetes and obesity. SGLT inhibitors are a new class of drugs for diabetes and obesity. They work differently from traditional Type 2 diabetes therapeutics which increase insulin production in the pancreas and affect metabolism. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.

The kidneys filter approximately 180 gm of glucose per day from the blood which is then mostly reabsorbed back into the blood by SGLT transporters. SGLT inhibitors reduce the glucose reabsorption process, such that excess glucose is excreted in the urine, rather than reabsorbed into the bloodstream. That is to say, they can help regulate glycemia. This is a new promising potential treatment for Type 2 diabetes and obesity.

Status & Milestones
Preclinical animal tests of Sirona Biochem's SGLT inhibitor for Type 2 diabetes are well underway with the positive results posted in the first quarter of 2011. Additional preclinical studies to test the safety and toxicology of this SGLT inhibitor are currently being conducted. Sirona Biochem plans to independently complete preclinical studies to prepare its SGLT inhibitor for human clinical trials. A pharmaceutical partner will be sought for clinical and commercial development of our program.

Watch the video on SBM's technology “ how it works:
http://www.youtube.com/watch?feature=player_embedded&v=F_fAzxsf7hk


About Sirona Biochem Corp (www.sironabiochem.com)
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

Become an Investorideas.com Member
http://www.investorideas.com/membership/

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894